A Randomized Controlled Clinical Trial Investigating the Effect of Synbiotic Administration on Markers of Insulin Metabolism and Lipid Profiles in Overweight Type 2 Diabetic Patients with Coronary Heart Disease

Abstract

The current study was performed to evaluate the effects of synbiotic administration on metabolic profiles in overweight diabetic patients with coronary heart disease (CHD). This randomized, double-blind, placebo-controlled trial was done among 60 diabetic patients with CHD. Participants were randomly divided into 2 groups: group A (n=30) received synbiotic supplements containing 3 probiotic bacteria spices 2×10, 2×10, 2×10 CFU/g plus 800 mg inulin and group B (n=30) received placebo for 12 weeks. Fasting blood samples were taken at baseline and after 12-week intervention to determine metabolic profiles. After 12 weeks of intervention, patients who consumed synbiotic capsule had significantly decreased fasting plasma glucose (- 19.6±74.6 vs.+19.2±66.9 mg/dL, P=0.03), serum insulin concentrations (- 0.7±5.1 vs.+3.3±6.3 µIU/mL, P=0.01), the homeostasis model of assessment-estimated b cell function (- 3.4±19.5 vs.+11.5±21.0, P=0.006) and increased the quantitative insulin sensitivity check index (+ 0.002±0.01 vs.-0.01±0.02, P=0.03) compared with the placebo. In addition, changes in HLDL-cholesterol levels (+ 1.8±5.7 vs.-2.2±6.0 mg/dL, P=0.01) in supplemented patients were significantly different from those of patients in the placebo group. Synbiotic supplementation for 12 weeks among diabetic patients with CHD had beneficial effects on markers of insulin metabolism and HDL-cholesterol levels.

Effects of probiotics on type II diabetes mellitus: a meta-analysis

“…The majority of the publications were excluded because they were irrelevant studies, case reports, or reviews. According to the inclusion and exclusion criteria, 15 publications (14 in English and 1 in Chinese) with a total of 902 patients were finally included [12,13,[15][16][17][18][19][20][21][22][23][24][25][26][27]. A flow chart showing the workflow for identifying and screening studies is presented in Fig.…”

Effects of a multispecies synbiotic on glucose metabolism, lipid marker, gut microbiome composition, gut permeability, and quality of life in diabesity: a randomized, double-blind, placebo-controlled pilot study

“…indigestible dietary compounds that increase the growth and activity of fibre fermenting bacteria) are linked to the increase of SCFA-producers in the intestine and have also been shown to improve glucose metabolism and meal handling in T2D [28][29][30][31]. Combinations of pro-and prebiotics, known as synbiotics, can exert beneficial effects on glycemic control and oxidative stress [32][33][34][35]. Thus, prebiotics might complement the effects of probiotics in diabesity patients.…”

The effects of synbiotic supplementation on metabolic factors and systemic inflammation in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study

“…Only serum LDL concentration in the treatment group decreased significantly after 6 months of intervention compared to the placebo group. In another study conducted by Ebrahimi et al [22] in 2017 on obese patients with type 2 diabetes, serum concentrations of triglyceride, total cholesterol, and LDL-cholesterol in the synbiotic supplemented group did not change significantly compared to the placebo group after 12 weeks of supplementation. However, the serum concentration of HDL-cholesterol was considerably higher in the synbiotic group than in the placebo group after treatment [22].…”